中度至重度斑块型银屑病-话题@MedSci

#中度至重度斑块型银屑病#

5篇内容 | 858人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1464190, encodeId=6e4f146419036, content=<a href='/topic/show?id=736f221484a' target=_blank style='color:#2F92EE;'>#中度至重度斑块型银屑病#</a>, objectTitle=欧洲CHMP对AbbVie的IL-23单抗Risankizumab治疗中度至重度斑块型银屑病作出积极评价, objectType=article, longId=161542, objectId=b41f1615426c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b41f1615426c, replyNumber=0, likeNumber=31, createdTime=2019-03-03, rootId=0, userName=lg.zhao, userId=2d186606178, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b41f1615426c, moduleTitle=欧洲CHMP对AbbVie的IL-23单抗Risankizumab治疗中度至重度斑块型银屑病作出积极评价, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b41f1615426c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1464189, encodeId=ca2e146418904, content=<a href='/topic/show?id=736f221484a' target=_blank style='color:#2F92EE;'>#中度至重度斑块型银屑病#</a>, objectTitle=美国FDA批准新型TREMFYA（guselkumab）制剂治疗成人中度至重度斑块型银屑病, objectType=article, longId=161432, objectId=c21f16143225, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c21f16143225, replyNumber=0, likeNumber=27, createdTime=2019-03-02, rootId=0, userName=lg.zhao, userId=2d186606178, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c21f16143225, moduleTitle=美国FDA批准新型TREMFYA（guselkumab）制剂治疗成人中度至重度斑块型银屑病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c21f16143225)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1464188, encodeId=71031464188cb, content=<a href='/topic/show?id=736f221484a' target=_blank style='color:#2F92EE;'>#中度至重度斑块型银屑病#</a>, objectTitle=Lilly将启动IXORA-R头对头试验：比较IL-17A单抗Taltz和IL-23单抗Tremfya治疗中度至重度斑块型银屑病患者的疗效, objectType=article, longId=148645, objectId=6dae148645a9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6dae148645a9, replyNumber=0, likeNumber=19, createdTime=2018-09-13, rootId=0, userName=lg.zhao, userId=2d186606178, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6dae148645a9, moduleTitle=Lilly将启动IXORA-R头对头试验：比较IL-17A单抗Taltz和IL-23单抗Tremfya治疗中度至重度斑块型银屑病患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6dae148645a9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1464187, encodeId=347c146418e48, content=<a href='/topic/show?id=736f221484a' target=_blank style='color:#2F92EE;'>#中度至重度斑块型银屑病#</a>, objectTitle=FDA扩大Cimzia的适应症：中度至重度斑块型银屑病, objectType=article, longId=139445, objectId=c77e139445ee, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c77e139445ee, replyNumber=0, likeNumber=28, createdTime=2018-05-31, rootId=0, userName=lg.zhao, userId=2d186606178, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c77e139445ee, moduleTitle=FDA扩大Cimzia的适应症：中度至重度斑块型银屑病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c77e139445ee)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1464186, encodeId=16591464186fa, content=<a href='/topic/show?id=736f221484a' target=_blank style='color:#2F92EE;'>#中度至重度斑块型银屑病#</a>, objectTitle=Br J Dermatol：Guselkumab治疗不同亚群的中度至重度斑块型银屑病，疗效依然较优, objectType=article, longId=114695, objectId=84bc114695d0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=84bc114695d0, replyNumber=0, likeNumber=26, createdTime=2017-09-30, rootId=0, userName=lg.zhao, userId=2d186606178, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=84bc114695d0, moduleTitle=Br J Dermatol：Guselkumab治疗不同亚群的中度至重度斑块型银屑病，疗效依然较优, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=84bc114695d0)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

中度至重度斑块型银屑病

2020-05-29

lg.zhao (审核中...)

前往app查看评论内容

#中度至重度斑块型银屑病#

欧洲CHMP对AbbVie的IL-23单抗Risankizumab治疗中度至重度斑块型银屑病作出积极评价

2019-03-03

lg.zhao (审核中...)

前往app查看评论内容

#中度至重度斑块型银屑病#

美国FDA批准新型TREMFYA（guselkumab）制剂治疗成人中度至重度斑块型银屑病

2019-03-02

lg.zhao (审核中...)

前往app查看评论内容

#中度至重度斑块型银屑病#

Lilly将启动IXORA-R头对头试验：比较IL-17A单抗Taltz和IL-23单抗Tremfya治疗中度至重度斑块型银屑病患者的疗效

2018-09-13

lg.zhao (审核中...)

前往app查看评论内容

#中度至重度斑块型银屑病#

FDA扩大Cimzia的适应症：中度至重度斑块型银屑病

2018-05-31

lg.zhao (审核中...)

前往app查看评论内容

#中度至重度斑块型银屑病#

Br J Dermatol：Guselkumab治疗不同亚群的中度至重度斑块型银屑病，疗效依然较优

2017-09-30

科室
- - 订阅+
  - 更多科室
工具
服务